Novo Holdings, a global life sciences investor, announced today its strategic investment in SCHOTT Poonawalla, a leading Indian manufacturer of drug containment and delivery solutions for injectable pharmaceuticals. The investment, made alongside TPG Growth, aims to accelerate growth and innovation in injectable drug packaging capabilities in the region.
SCHOTT Poonawalla, established as a joint venture between SCHOTT Pharma AG and the Serum Institute of India, has positioned itself as India's foremost provider of injectable-focused primary packaging. The company manufactures a comprehensive range of products including ampoules, vials, cartridges, and prefilled syringes at its three manufacturing facilities across India.
Strategic Significance for Pharmaceutical Supply Chain
With an annual production capacity exceeding 3 billion units, SCHOTT Poonawalla serves more than 100 pharmaceutical customers, playing a critical role in the injectable drug supply chain. The investment underscores Novo Holdings' recognition of the strategic importance of high-quality drug delivery systems and India's pivotal role in global pharmaceutical manufacturing.
"Our investment in SCHOTT Poonawalla reflects our conviction in the strategic importance of high-quality drug delivery systems and the critical role India plays in the global pharmaceutical supply chain," said Amit Kakar, Managing Partner and Head of Asia at Novo Holdings. "We look forward to supporting SCHOTT Poonawalla's next phase of growth alongside TPG and SCHOTT Pharma and help expand its global footprint while ensuring resilient and sustainable supply of essential packaging solutions."
Expanding Novo Holdings' Presence in Asia
This investment marks Novo Holdings' first venture into the medtech manufacturing space in India and aligns with its strategy to support category-defining life sciences platforms globally. The move further strengthens Novo Holdings' presence in the pharmaceutical infrastructure segment and demonstrates its commitment to building long-term partnerships with differentiated healthcare platforms in Asia.
Navjeewan Khosla, Partner at Novo Holdings Asia, highlighted the strategic fit: "SCHOTT Poonawalla is a clear market leader in India's injectable packaging space, with a strong reputation for quality, innovation, and reliability. We see significant opportunity to add value by leveraging Novo Holdings' life sciences network, experience in medtech, and strong global partnerships across the biopharma industry."
Manufacturing Excellence and Market Position
Founded in 1990 as a premium manufacturer of tubular glass pharmaceutical containers, SCHOTT Poonawalla has established itself as an expert in premium parenteral packaging systems. The company operates as a 50-50 joint venture with SCHOTT Pharma AG & Co. KGaA, Germany, an international technology group and leading expert in glass parenteral packaging.
The company's extensive product portfolio caters to the pharmaceutical industry's growing demand for high-quality containment solutions for injectable medications. As injectable therapies continue to grow in importance across the pharmaceutical landscape, reliable packaging that ensures drug stability, safety, and efficacy becomes increasingly critical.
Future Growth Trajectory
Novo Holdings plans to support SCHOTT Poonawalla's expansion through value creation initiatives and long-term engagement. The investment is expected to enhance the company's innovation capabilities, expand its manufacturing footprint, and strengthen its position in both domestic and international markets.
With Novo Holdings' extensive life sciences network and TPG's growth equity expertise, SCHOTT Poonawalla is well-positioned to capitalize on the increasing global demand for injectable drug packaging solutions while maintaining its commitment to quality and reliability.
The financial details of the transaction were not disclosed.
